Carbonic Anhydrase IX Enzyme in Triple Negative Breast Carcinoma

Status Completed

Clinical Trial Summary

Triple-negative breast carcinoma is characterized by the absence of estrogen receptors, progesterone receptors, and HER2/neu receptors. Carbonic anhydrase IX (CA IX) is a tumor-associated cell surface glycoprotein that is involved in adaptation to hypoxia-induced acidosis and plays a role in cancer progression. This study aimed to investigate CA IX expression in TNBC and its relationship with treatment effect.

Clinical Trial Description

Tru-cut biopsy materials, sent to our hospital pathology laboratory between August 2018 and May 2023, will be examined. Invasive carcinoma cases will be evaluated according to estrogen, progesterone, and HER 2 receptor levels. Triple-negative tumor cases were isolated and those cases who underwent breast resection in our hospital after receiving neoadjuvant chemotherapy (Adriamycin, cyclophosphamide, and then paclitaxel for 4 cycles) were included in the study. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT06309459
Study type	Observational
Source	Kahramanmaras Sutcu Imam University
Contact
Status	Completed
Phase
Start date	August 1, 2018
Completion date	May 1, 2023

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT05174832` - Induction of Cisplatin/Nab-paclitaxel/Pembrolizumab Followed by Olaparib/Pembrolizumab Maintenance in mTNBC Patients	Phase 2
Active, not recruiting	`NCT03667716` - COM701 (an Inhibitor of PVRIG) in Subjects With Advanced Solid Tumors.	Phase 1
Withdrawn	`NCT03634150` - Safety and Efficacy of IV Nerofe™ Followed by Doxorubicin, In Metastatic Ovarian Cancer and Triple Negative Breast Cancer	Phase 1/Phase 2
Recruiting	`NCT03348098` - Clinical Study of Neoadjuvant Therapy With Apatinib and Paclitaxel in Local Advanced Triple-negative Breast Cancer	Phase 2
Completed	`NCT04032080` - LY3023414 and Prexasertib in Metastatic Triple-negative Breast Cancer	Phase 2
Active, not recruiting	`NCT03170960` - Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors	Phase 1/Phase 2
Withdrawn	`NCT02427581` - Safety and Immunogenicity of a Personalized Synthetic Long Peptide Breast Cancer Vaccine Strategy in Patients With Persistent Triple-Negative Breast Cancer Following Neoadjuvant Chemotherapy	Phase 1
Recruiting	`NCT03165487` - Comparison of the Breast Tumor Microenvironment
Completed	`NCT02225470` - Eribulin Versus Vinorelbine in Subjects With Locally Recurrent or Metastatic Breast Cancer Previously Treated With Anthracyclines and Taxanes	Phase 3
Recruiting	`NCT04452370` - Oral Etoposide Combined With Anlotinib in Advanced Triple Negative Breast Cancer	Phase 2
Terminated	`NCT04123704` - Sitravatinib in Metastatic Breast Cancer	Phase 2
Recruiting	`NCT04758780` - Imaging Performance Assessment of 89Zirconium-labelled Girentuximab (89Zr-TLX250) PET-CT in Metastatic Triple Negative Breast Cancer Patients	Phase 2
Withdrawn	`NCT04268693` - Bisphenol and Phthalate Exposures in Triple Negative Breast Cancer
Withdrawn	`NCT03982173` - Basket Trial for Combination Therapy With Durvalumab (Anti-PDL1) (MEDI4736) and Tremelimumab (Anti-CTLA4) in Patients With Metastatic Solid Tumors	Phase 2
Not yet recruiting	`NCT02685657` - Neoadjuvant Chemotherapy Docetaxel With or Without SELUMETINIB in Patients With Triple Negative Breast Cancer	Phase 2
Terminated	`NCT01918306` - GDC-0941 and Cisplatin in Treating Patients With Androgen Receptor-Negative Triple Negative Metastatic Breast Cancer	Phase 1/Phase 2
Completed	`NCT01276899` - Study to Identify Molecular Mechanisms of Clinical Resistance to Chemotherapy in Triple Negative Breast Cancer Patients
Completed	`NCT00998036` - Study of Temsirolimus, Erlotinib and Cisplatin in Solid Tumors	Phase 1
Recruiting	`NCT05309655` - Cardiac Outcomes With Near-Complete Estrogen Deprivation	Early Phase 1
Active, not recruiting	`NCT03267316` - A First-in-Human Study of CAN04 in Patients With Solid Malignant Tumors	Phase 1/Phase 2